Necessary to Identify Latent Toxicants A

Mousa Bamir, Salman Daneshi, Salman Farahbakhsh

Abstract


Dear Editor SARS‑CoV‑2 is a new coronavirus that emerged in 2019 and caused the COVID‑19 epidemic, but despite much effort, there is still no specific care standard. The lack of accurate information posed several challenges for health systems, which were accompanied by a wide range of possibly unfamiliar materials for the treatment and prevention of COVID‑19.[1] When a major medical crisis such as COVID‑19 occurs, and there is no known cure for it, several phenomena may occur, and people to show different behavioral reactions to deal with this condition and treat it with limited knowledge.

Keywords


COVID‑19; Coronavirus; Latent Toxicants; SARS‑CoV‑2

Full Text:

PDF

References


Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM.

COVID‑19: Therapeutics and their toxicities. J Med Toxicol

;16:284‑94.

Kara E, Inkaya AC, Demirkan K. May drug‑related

cardiovascular toxicities persist after hospital discharge in

COVID‑19 patients? Int J Antimicrob Agents 2020;55:106003.

Neumann NR, Chai PR, Wood DM, Greller HA, Mycyk MB.

Medical toxicology and COVID‑19: Our role in a pandemic.

J Med Toxicol 2020;16:245‑7.

Aminpour M, Delgado WE, Wacker S, Noskov S, Houghton M,

Tyrrell DL, et al. Computational determination of toxicity risks

associated with a selection of approved drugs having demonstrated

activity against COVID‑19. BMC Pharmacol Toxicol 2021;22:61.